F Borja de Lacy1, Jacqueline J E M van Laarhoven2, Romina Pena3, María Clara Arroyave4, Raquel Bravo3, Miriam Cuatrecasas5, Antonio M Lacy3. 1. Department of Gastrointestinal Surgery, Institute of Digestive and Metabolic Diseases, AIS Channel, Hospital Clínic Barcelona, Villarroel 170, 08036, Barcelona, Spain. borjalacy@gmail.com. 2. Department of Gastrointestinal Surgery, AIS Channel, Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, The Netherlands. 3. Department of Gastrointestinal Surgery, Institute of Digestive and Metabolic Diseases, AIS Channel, Hospital Clínic Barcelona, Villarroel 170, 08036, Barcelona, Spain. 4. Department of Surgical Oncology, AIS Channel, Clinica Somer, Rionegro, Colombia. 5. Department of Pathology, Institute of Biomedical Diagnostic Center, AIS Channel, Hospital Clínic Barcelona, Barcelona, Spain.
Abstract
BACKGROUND: Transanal total mesorectal excision (TaTME) seems to be a valid alternative to the open or laparoscopic TME. Quality of the TME specimen is the most important prognostic factor in rectal cancer. This study shows the pathological results of the largest single-institution series published on TaTME in patients with mid and low rectal cancer. METHODS: We conducted a retrospective cohort study of all consecutive patients with rectal cancer, treated by TaTME between November 2011 and June 2016. Patient data were prospectively included in a standardized database. Patients with all TNM stages of mid (5-10 cm from the anal verge) and low (0-5 cm from the anal verge) rectal cancer were included. RESULTS: A total of 186 patients were included. Tumor was in the mid and low rectum in, respectively, 62.9 and 37.1%. Neoadjuvant chemoradiotherapy was given in 62.4%, only radiotherapy in 3.2%, and only chemotherapy in 2.2%. Preoperative staging showed T1 in 3.2%, T2 in 20.4%, T3 in 67.7%, and T4 in 7.5%. Mesorectal resection quality was complete in 95.7% (n = 178), almost complete in 1.6% (n = 3), and incomplete in 1.1% (n = 2). Overall positive CRM (≤ 1 mm) and DRM (≤ 1 mm) were 8.1% (n = 15) and 3.2% (n = 6), respectively. The composite of complete mesorectal excision, negative CRM, and negative DRM was achieved in 88.1% (n = 155) of the patients. The median number of lymph nodes found per specimen was 14.0 (IQR 11-18). CONCLUSIONS: The present study showed good rates regarding total mesorectal excision, negative circumferential, and distal resection margins. As the specimen quality is a surrogate marker for survival, TaTME can be regarded as a safe method to treat patients with rectal cancer, from an oncological point of view.
BACKGROUND: Transanal total mesorectal excision (TaTME) seems to be a valid alternative to the open or laparoscopic TME. Quality of the TME specimen is the most important prognostic factor in rectal cancer. This study shows the pathological results of the largest single-institution series published on TaTME in patients with mid and low rectal cancer. METHODS: We conducted a retrospective cohort study of all consecutive patients with rectal cancer, treated by TaTME between November 2011 and June 2016. Patient data were prospectively included in a standardized database. Patients with all TNM stages of mid (5-10 cm from the anal verge) and low (0-5 cm from the anal verge) rectal cancer were included. RESULTS: A total of 186 patients were included. Tumor was in the mid and low rectum in, respectively, 62.9 and 37.1%. Neoadjuvant chemoradiotherapy was given in 62.4%, only radiotherapy in 3.2%, and only chemotherapy in 2.2%. Preoperative staging showed T1 in 3.2%, T2 in 20.4%, T3 in 67.7%, and T4 in 7.5%. Mesorectal resection quality was complete in 95.7% (n = 178), almost complete in 1.6% (n = 3), and incomplete in 1.1% (n = 2). Overall positive CRM (≤ 1 mm) and DRM (≤ 1 mm) were 8.1% (n = 15) and 3.2% (n = 6), respectively. The composite of complete mesorectal excision, negative CRM, and negative DRM was achieved in 88.1% (n = 155) of the patients. The median number of lymph nodes found per specimen was 14.0 (IQR 11-18). CONCLUSIONS: The present study showed good rates regarding total mesorectal excision, negative circumferential, and distal resection margins. As the specimen quality is a surrogate marker for survival, TaTME can be regarded as a safe method to treat patients with rectal cancer, from an oncological point of view.
Authors: E Kapiteijn; C A Marijnen; I D Nagtegaal; H Putter; W H Steup; T Wiggers; H J Rutten; L Pahlman; B Glimelius; J H van Krieken; J W Leer; C J van de Velde Journal: N Engl J Med Date: 2001-08-30 Impact factor: 91.245
Authors: Marta Penna; Roel Hompes; Steve Arnold; Greg Wynn; Ralph Austin; Janindra Warusavitarne; Brendan Moran; George B Hanna; Neil J Mortensen; Paris P Tekkis Journal: Ann Surg Date: 2017-07 Impact factor: 12.969
Authors: María Fernández-Hevia; Salvadora Delgado; Antoni Castells; Marta Tasende; Dulce Momblan; Gabriel Díaz del Gobbo; Borja DeLacy; Jaume Balust; Antonio M Lacy Journal: Ann Surg Date: 2015-02 Impact factor: 12.969
Authors: James J Mezhir; Kerrington D Smith; Alessandro Fichera; John Hart; Mitchell C Posner; Roger D Hurst Journal: Surgery Date: 2005-10 Impact factor: 3.982
Authors: K Zaghiyan; J Warusavitarne; A Spinelli; P Chandrasinghe; F Di Candido; P Fleshner Journal: Tech Coloproctol Date: 2018-12-11 Impact factor: 3.781
Authors: Evie Carchman; Daniel I Chu; Gregory D Kennedy; Melanie Morris; Marc Dakermandji; John R T Monson; Laura Melina Fernandez; Rodrigo Oliva Perez; Alessandro Fichera; Marco E Allaix; David Liska Journal: J Gastrointest Surg Date: 2018-09-13 Impact factor: 3.452
Authors: David A Westwood; Tahleesa J Cuda; A E Ricardo Hamilton; David Clark; Andrew R L Stevenson Journal: Tech Coloproctol Date: 2018-09-25 Impact factor: 3.781